written by reader Uveitis Development orphan status

By xiexgp@gmail.com, November 20, 2014

I just read (watched) a presentation from Mike Ward of Wall Street Insights & indictments for a biotech newsletter touting a $4 stock for a $28 million California company that has just received (or is about to) orphan status for a new Uveitis drug.

ABBV has one listed, but is a $65 stock.

Any one have a clue as to what this company is?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.